Adma Biologics reported $34.41M in Cash and Equivalent for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Adma Biologics ADMA:US $ 34.41M 8M
Agile Therapeutics AGRX:US $ 14.74M 11.38M
Alnylam Pharmaceuticals ALNY:US $ 1093.99M 348.22M
Biocryst Pharmaceuticals BCRX:US $ 199.6M 10.72M
China Cord Blood CO:US 6.39B 153.23M
Dynavax Technologies DVAX:US $ 246.35M 116.74M
Kindred Biosciences KIN:US $ 46.72M 33.8M
Minerva Neurosciences NERV:US $ 65.59M 8.63M
Novavax NVAX:US $ 366.24M 128.21M
Omeros OMER:US $ 7.42M 5.29M
Takeda 4502:JP Y 607881M 47039M